Low glycemic index treatment in patients with drug-resistant epilepsy

Se Hee Kim, Hoon Chul Kang, Eun Joo Lee, Joon Soo Lee, Heung Dong Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective Low glycemic index treatment (LGIT) is a newly developed dietary therapeutic option for epilepsy that is less restrictive than the ketogenic diet (KD). Our objective was to determine the efficacy and tolerability of LGIT. Methods From March 2014 to February 2015, 36 patients received LGIT at Severance Children's Hospital. One-year seizure outcomes and side effects were evaluated. Results A total of 36 patients were assessed. Fourteen were female. Common diagnoses were Lennox-Gastaut syndrome (33%, 12/36) and Dravet syndrome (14%, 5/36). The median age at the initiation of the LGIT was 12.6 years (min. = 1.5, max. = 28, interquartile range (IQR) 8–17). After 3 months of therapy, 20 (56%) patients experienced a 50% or greater reduction in seizure frequency, which was maintained in 19 (53%) patients for 1 year. Two (6%) patients became seizure-free after 3 months of LGIT; they remained seizure-free for 1 year. These two had Dravet syndrome and generalized epilepsy. Only three (8%) patients discontinued treatment within 1 year. Adverse events were rare, and two patients (6%) reported transient diarrhea. Conclusions LGIT effectively reduced seizure frequency in the present study, although seizure freedom was infrequently achieved. LGIT may be considered as a therapeutic option for patients with drug-resistant epilepsy, particularly those who find KD effective but intolerable.

Original languageEnglish
Pages (from-to)687-692
Number of pages6
JournalBrain and Development
Volume39
Issue number8
DOIs
Publication statusPublished - 2017 Sep

Fingerprint

Glycemic Index
Seizures
Therapeutics
Ketogenic Diet
Myoclonic Epilepsy
Drug Resistant Epilepsy
Generalized Epilepsy
Diarrhea
Epilepsy

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Kim, Se Hee ; Kang, Hoon Chul ; Lee, Eun Joo ; Lee, Joon Soo ; Kim, Heung Dong. / Low glycemic index treatment in patients with drug-resistant epilepsy. In: Brain and Development. 2017 ; Vol. 39, No. 8. pp. 687-692.
@article{a0855023f92545b9a17860b6f13af280,
title = "Low glycemic index treatment in patients with drug-resistant epilepsy",
abstract = "Objective Low glycemic index treatment (LGIT) is a newly developed dietary therapeutic option for epilepsy that is less restrictive than the ketogenic diet (KD). Our objective was to determine the efficacy and tolerability of LGIT. Methods From March 2014 to February 2015, 36 patients received LGIT at Severance Children's Hospital. One-year seizure outcomes and side effects were evaluated. Results A total of 36 patients were assessed. Fourteen were female. Common diagnoses were Lennox-Gastaut syndrome (33{\%}, 12/36) and Dravet syndrome (14{\%}, 5/36). The median age at the initiation of the LGIT was 12.6 years (min. = 1.5, max. = 28, interquartile range (IQR) 8–17). After 3 months of therapy, 20 (56{\%}) patients experienced a 50{\%} or greater reduction in seizure frequency, which was maintained in 19 (53{\%}) patients for 1 year. Two (6{\%}) patients became seizure-free after 3 months of LGIT; they remained seizure-free for 1 year. These two had Dravet syndrome and generalized epilepsy. Only three (8{\%}) patients discontinued treatment within 1 year. Adverse events were rare, and two patients (6{\%}) reported transient diarrhea. Conclusions LGIT effectively reduced seizure frequency in the present study, although seizure freedom was infrequently achieved. LGIT may be considered as a therapeutic option for patients with drug-resistant epilepsy, particularly those who find KD effective but intolerable.",
author = "Kim, {Se Hee} and Kang, {Hoon Chul} and Lee, {Eun Joo} and Lee, {Joon Soo} and Kim, {Heung Dong}",
year = "2017",
month = "9",
doi = "10.1016/j.braindev.2017.03.027",
language = "English",
volume = "39",
pages = "687--692",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",
number = "8",

}

Low glycemic index treatment in patients with drug-resistant epilepsy. / Kim, Se Hee; Kang, Hoon Chul; Lee, Eun Joo; Lee, Joon Soo; Kim, Heung Dong.

In: Brain and Development, Vol. 39, No. 8, 09.2017, p. 687-692.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low glycemic index treatment in patients with drug-resistant epilepsy

AU - Kim, Se Hee

AU - Kang, Hoon Chul

AU - Lee, Eun Joo

AU - Lee, Joon Soo

AU - Kim, Heung Dong

PY - 2017/9

Y1 - 2017/9

N2 - Objective Low glycemic index treatment (LGIT) is a newly developed dietary therapeutic option for epilepsy that is less restrictive than the ketogenic diet (KD). Our objective was to determine the efficacy and tolerability of LGIT. Methods From March 2014 to February 2015, 36 patients received LGIT at Severance Children's Hospital. One-year seizure outcomes and side effects were evaluated. Results A total of 36 patients were assessed. Fourteen were female. Common diagnoses were Lennox-Gastaut syndrome (33%, 12/36) and Dravet syndrome (14%, 5/36). The median age at the initiation of the LGIT was 12.6 years (min. = 1.5, max. = 28, interquartile range (IQR) 8–17). After 3 months of therapy, 20 (56%) patients experienced a 50% or greater reduction in seizure frequency, which was maintained in 19 (53%) patients for 1 year. Two (6%) patients became seizure-free after 3 months of LGIT; they remained seizure-free for 1 year. These two had Dravet syndrome and generalized epilepsy. Only three (8%) patients discontinued treatment within 1 year. Adverse events were rare, and two patients (6%) reported transient diarrhea. Conclusions LGIT effectively reduced seizure frequency in the present study, although seizure freedom was infrequently achieved. LGIT may be considered as a therapeutic option for patients with drug-resistant epilepsy, particularly those who find KD effective but intolerable.

AB - Objective Low glycemic index treatment (LGIT) is a newly developed dietary therapeutic option for epilepsy that is less restrictive than the ketogenic diet (KD). Our objective was to determine the efficacy and tolerability of LGIT. Methods From March 2014 to February 2015, 36 patients received LGIT at Severance Children's Hospital. One-year seizure outcomes and side effects were evaluated. Results A total of 36 patients were assessed. Fourteen were female. Common diagnoses were Lennox-Gastaut syndrome (33%, 12/36) and Dravet syndrome (14%, 5/36). The median age at the initiation of the LGIT was 12.6 years (min. = 1.5, max. = 28, interquartile range (IQR) 8–17). After 3 months of therapy, 20 (56%) patients experienced a 50% or greater reduction in seizure frequency, which was maintained in 19 (53%) patients for 1 year. Two (6%) patients became seizure-free after 3 months of LGIT; they remained seizure-free for 1 year. These two had Dravet syndrome and generalized epilepsy. Only three (8%) patients discontinued treatment within 1 year. Adverse events were rare, and two patients (6%) reported transient diarrhea. Conclusions LGIT effectively reduced seizure frequency in the present study, although seizure freedom was infrequently achieved. LGIT may be considered as a therapeutic option for patients with drug-resistant epilepsy, particularly those who find KD effective but intolerable.

UR - http://www.scopus.com/inward/record.url?scp=85017608494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017608494&partnerID=8YFLogxK

U2 - 10.1016/j.braindev.2017.03.027

DO - 10.1016/j.braindev.2017.03.027

M3 - Article

C2 - 28431772

AN - SCOPUS:85017608494

VL - 39

SP - 687

EP - 692

JO - Brain and Development

JF - Brain and Development

SN - 0387-7604

IS - 8

ER -